US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy

Complement Therapeutics GmbH, a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, announced that the US Food and Drug Administration (FDA) has

To access the full article, please log in or subscribe.